2017
DOI: 10.1161/strokeaha.117.018377
|View full text |Cite
|
Sign up to set email alerts
|

Intracerebral Hemorrhage and Outcome After Thrombolysis in Stroke Patients Using Selective Serotonin-Reuptake Inhibitors

Abstract: Preadmission treatment with SSRIs was not significantly associated with an increased risk of post-thrombolysis sICH in this cohort study. However, subgroup analysis suggested an increased risk of sICH in patients taking both SSRI and OAC. Preadmission treatment with SSRIs was associated with unfavorable outcome, which may reflect the prognostic significance of prestroke depression.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
21
0
3

Year Published

2018
2018
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 25 publications
(24 citation statements)
references
References 33 publications
0
21
0
3
Order By: Relevance
“…In a large collaborative study, the preadmission use of SSRI alone did not increase the risk of spontaneous intracerebral hemorrhage after intravenous thrombolytic therapy for acute ischemic stroke. While there was a significant interaction between the concurrent preadmission use of SSRIs and oral anticoagulants on the occurrence of intracerebral hemorrhage related to thrombolysis[ 53 ], this condition can be seen in PSD patients with recurrent acute ischemic stroke that are treated with SSRIs. Moreover, fluoxetine and fluvoxamine are reported to have potential interactions with warfarin, and inhibit warfarin metabolism by competitively binding plasma protein and interfering with CYP isoenzymes, which are more likely to strengthen the anticoagulant effects of warfarin.…”
Section: Depressive Disorders After Strokementioning
confidence: 99%
“…In a large collaborative study, the preadmission use of SSRI alone did not increase the risk of spontaneous intracerebral hemorrhage after intravenous thrombolytic therapy for acute ischemic stroke. While there was a significant interaction between the concurrent preadmission use of SSRIs and oral anticoagulants on the occurrence of intracerebral hemorrhage related to thrombolysis[ 53 ], this condition can be seen in PSD patients with recurrent acute ischemic stroke that are treated with SSRIs. Moreover, fluoxetine and fluvoxamine are reported to have potential interactions with warfarin, and inhibit warfarin metabolism by competitively binding plasma protein and interfering with CYP isoenzymes, which are more likely to strengthen the anticoagulant effects of warfarin.…”
Section: Depressive Disorders After Strokementioning
confidence: 99%
“…To assess the association between SaO and the respective outcome measures we used the following methods: Unadjusted logistic regression. Logistic regression adjusted for confounding by the following potentially outcome‐modifying parameters, as in prior research: age, sex, NIHSS on admission, prior antithrombotic treatment, glucose and eGFR on admission, EVT in addition to IVT, onset‐to‐treatment time, prior dependence, and prior stroke. Missing values in these variables were imputed using 5 multiple imputations according to van Buuren and Groothuis–Oudshoorn …”
Section: Methodsmentioning
confidence: 99%
“…21 It remains unclear whether the same can be said for PSD or vascular depression; notably, chronic SSRI treatment increases the risk of hemorrhage. 22,23 However, to examine treatment outcomes for vascular depression, it will be necessary to first detect it using imaging, as mentioned earlier.…”
Section: Does Psd/vascular Depression Respond To Antidepressant Treatmentioning
confidence: 99%